Prevalence of neurogenic orthostatic hypotension in the idiopathic Parkinson Progression Marker Initiative cohort.
Objective: To assess prevalence of neurogenic and peripheral orthostatic hypotension (nOH/pOH) in the PPMI (https://www.ppmi-info.org) idiopathic Parkinson disease (PD) cohort and to examine whether nOH,…Locus coeruleus volume is reduced in Parkinson disease-related orthostatic hypotension.
Objective: To test whether structural pathology of the locus coeruleus (LC) is associated with orthostatic hypotension (OH) in Parkinson disease (PD). Background: OH is an…Leg muscle contractions compensate for declining cardiac baroreflex in PD Patients
Objective: To investigate if impairments in muscle contraction affects blood pressure (BP) regulation in PD. Background: Orthostatic hypotension (OH) contributes to unexpected falls in PD.…Both Symptomatic and Asymptomatic Orthostatic Hypotension is Associated with Cognitive Decline Over Time in Parkinson’s Disease
Objective: To compare cognitive changes over time between Parkinson's disease (PD) patients with orthostatic hypotension (OH) and without OH, and between those with symptomatic OH…Orthostatic hypotension in Parkinson’s disease
Objective: We aimed to identify whether orthostatic hypotension (OH) is a prodromal marker of Parkinson’s disease (PD) or a symptom of later disease. Background: Many…Orthostatic hypotension in early onset Parkinson’s disease
Objective: To investigate Orthostatic hypotension (OH) feature in early onset Parkinson's disease (EOPD) , especially delayed OH and acute OH post drug. To explore OH…The Clinical Heterogeneity of Orthostatic Hypotension in PD Patients
Objective: The objects of the research were to investigate the clinical heterogeneity of orthostatic hypotension(OH) in PD Patients, to explore the possible risk factors for…Ampreloxetine (TD-9855), a long-acting, norepinephrine reuptake inhibitor (NRI) for the treatment of neurogenic orthostatic hypotension (nOH) in subjects with synucleinopathies: Phase 3 clinical program
Objective: To confirm: 1) clinical efficacy and safety of once-daily oral ampreloxetine in a 4-week double-blind (DB), placebo-controlled (PC) study (NCT03750552); 2) durability of efficacy…Treatment of Neurogenic Orthostatic Hypotension (nOH) in Multiple System Atrophy (MSA) with a wearable Pneumatic Compression Garment utilising Soft Robotics
Objective: To use a novel Pneumatic Garment device for treatment of nOH in MSA. Background: nOH is present in 66-90% of patients with MSA and…Heart Rate Variability and Cognitive Impairment in Parkinson’s Disease
Objective: To evaluate the association between the heart rate variability (HRV) and cognitive impairment in PD patients. Background: Emerging evidence suggests an association between cognitive…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 9
- Next Page »